$60.16
0.23% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US23282W6057
Symbol
CYTK

Cytokinetics, Incorporated Stock price

$60.16
-0.01 0.02% 1M
+27.12 82.08% 6M
+13.12 27.89% YTD
+4.32 7.74% 1Y
+23.65 64.78% 3Y
+43.30 256.82% 5Y
+47.87 389.50% 10Y
+8.08 15.51% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
-0.14 0.23%

Key metrics

Basic
Market capitalization
$7.2b
Enterprise Value
$7.1b
Net debt
positive
Cash
$858.1m
Shares outstanding
119.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
84.2 | 84.2
EV/Sales
82.6 | 82.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-9.7%
Return on Equity
435.5%
ROCE
-50.0%
ROIC
-
Debt/Equity
-2.0
Financials (TTM | estimate)
Revenue
$85.7m | $85.6m
EBITDA
$-537.6m | $-630.8m
EBIT
$-547.0m | $-639.6m
Net Income
$-606.3m | $-685.6m
Free Cash Flow
$-438.7m
Growth (TTM | estimate)
Revenue
2,630.6% | 363.7%
EBITDA
-9.0% | -19.8%
EBIT
-8.1% | -19.3%
Net Income
-11.2% | -16.3%
Free Cash Flow
-9.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-627.0% | -736.5%
EBIT
-638.0%
Net
-707.2% | -800.5%
Free Cash Flow
-511.7%
More
EPS
$-5.1
FCF per Share
$-3.7
Short interest
15.5%
Employees
498
Rev per Employee
$40.0k
Show more

Is Cytokinetics, Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Cytokinetics, Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Cytokinetics, Incorporated forecast:

21x Buy
81%
5x Hold
19%

Analyst Opinions

26 Analysts have issued a Cytokinetics, Incorporated forecast:

Buy
81%
Hold
19%

Financial data from Cytokinetics, Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
86 86
2,631% 2,631%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 242 242
34% 34%
282%
- Research and Development Expense 391 391
19% 19%
456%
-538 -538
9% 9%
-627%
- Depreciation and Amortization 9.38 9.38
27% 27%
11%
EBIT (Operating Income) EBIT -547 -547
8% 8%
-638%
Net Profit -606 -606
11% 11%
-707%

In millions USD.

Don't miss a Thing! We will send you all news about Cytokinetics, Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytokinetics, Incorporated Stock News

Neutral
PRNewsWire
about 20 hours ago
LOS ANGELES , Nov. 7, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics " or "the Company") (NASDAQ: CYTK ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CYTK du...
Neutral
Business Wire
one day ago
NEW YORK--(BUSINESS WIRE)---- $CYTK #CYTK--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of doll...
Neutral
Seeking Alpha
2 days ago
Cytokinetics, Incorporated ( CYTK ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Diane Weiser - Senior Vice President of Corporate Affairs Robert I. Blum - CEO, President & Director Andrew Callos - Executive VP & Chief Commercial Officer Fady Malik - Executive Vice President of Research & Development Stuart Kupfer - Senior VP & Chief Medical Officer Sung Lee - EVP & C...
More Cytokinetics, Incorporated News

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Head office United States
CEO Robert Blum
Employees 498
Founded 1997
Website cytokinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today